Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study

Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study

Background: The efficacy and effectiveness of nintedanib as a first-line therapy in idiopathic pulmonary fibrosis (IPF) patients have been demonstrated by clinical trials and real-life studies. Our aim was to examine the safety profile and effectiveness of nintedanib when it is utilized as a second-...

Full description

Bibliographic Details
Main Authors: Andrea Vianello, Francesco Salton, Beatrice Molena, Cristian Turato, Maria Laura Graziani, Fausto Braccioni, Valeria Frassani, Dino Sella, Paolo Pretto, Luciana Paladini, Andi Sukthi, Marco Confalonieri
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Journal of Clinical Medicine
Subjects:
idiopathic pulmonary fibrosis
pirfenidone
nintedanib
adverse event
forced vital capacity
Online Access:https://www.mdpi.com/2077-0383/9/2/422

Internet

https://www.mdpi.com/2077-0383/9/2/422

Similar Items